Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Holdings Boosted by RTW Investments LP

RTW Investments LP raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,818,641 shares of the company's stock after purchasing an additional 431,503 shares during the quarter. Dyne Therapeutics comprises approximately 3.5% of RTW Investments LP's portfolio, making the stock its 8th largest holding. RTW Investments LP owned about 6.70% of Dyne Therapeutics worth $244,926,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DYN. Nisa Investment Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock worth $26,000 after purchasing an additional 669 shares during the period. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the 3rd quarter worth $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter worth $36,000. US Bancorp DE boosted its holdings in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the third quarter worth about $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ:DYN traded down $1.70 during mid-day trading on Thursday, hitting $27.74. 631,635 shares of the company's stock traded hands, compared to its average volume of 1,463,396. The company has a market cap of $2.82 billion, a PE ratio of -8.03 and a beta of 1.09. The firm's 50 day simple moving average is $31.34 and its 200 day simple moving average is $35.44. Dyne Therapeutics, Inc. has a 1 year low of $10.33 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on DYN. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Piper Sandler restated an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Chardan Capital reiterated a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Stifel Nicolaus raised their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a report on Friday, August 16th. Finally, Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $50.82.

Insiders Place Their Bets

In related news, Director Carlo Incerti sold 16,500 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Susanna Gatti High sold 8,976 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This trade represents a 6.38 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 176,257 shares of company stock valued at $6,193,718. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.